Skip to main content
Insights
/ white papers

The 7%: How leading pharma BD teams are pulling ahead with AI

Only 7% of pharma companies have AI genuinely embedded in their daily BD operations. This report examines what separates that 7% from the rest and what AI powered looks like.

The report presents the two pillars of AI adoption, what AI-powered BD looks like in practice, and how to benchmark where your organization sits today.

Share:
The 7%: How leading pharma BD teams are pulling ahead with AI

Download the white paper

Business email
First name
Last name
Company name
Job title
Which sector best reflects your role?
By submitting this form, you agree to receive email communications from Inpart as well as the storing and processing of your personal data by Inpart as detailed in the Privacy Statement. You may unsubscribe from these communications at any time.

What’s inside?

The framework of AI adoption  How the two pillars of AI adoption determine where your organization sits across three maturity levels: Foundational, AI Ready, and AI Powered.

The path forward  Three steps to move from reporting what happened to directing what's next, with practical actions at each stage.

Who this resource is for

This report is for BD and Alliance Management leaders who need to move faster on external opportunities without sacrificing decision quality and want to build AI capability without creating new bottlenecks. It covers what best-in-class AI adoption looks like and how to move from AI-ready to AI-powered.

What AI-embedded BD looks like

Sourcing signals 

Between 2025 and 2030, more than $300 billion in prescription drug revenues will lose patent exclusivity. How are AI-powered teams generating competitive landscapes, screening conference opportunities, and arriving at every interaction already informed?

Evaluating faster 

More than 50% of pharma companies are now sourcing assets at Phase II or earlier, meaning evaluation decisions are being made with less clinical evidence and under greater time pressure. How are leading teams reducing the time between first look and structured assessment?

Managing at scale 

Large pharma organizations routinely manage dozens of active alliances simultaneously, each with its own governance structure and milestone calendar. How is AI being applied to monitor alliance health continuously and flag escalation risks before governance meetings?

Is your BD function AI-ready?

This five-minute diagnostic benchmarks your BD function against the two pillars of AI readiness and tells you exactly where to focus next.

Take the diagnostic